ArticleNature communications2026
COVID-19-related inflammation of the placenta impedes fetal development in pregnant hamsters.
Yana Kumpanenko, Elke Maas, Joran Degryse, Birgit Weynand, Hilde Van de Velde, Johan Neyts, Katrien De Clercq, Yeranddy A Alpizar, Kai Dallmeier
Abstract read
In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Yana KumpanenkoKU Leuven Department of Microbiology, Immunology & Transplantation, Rega Institute, Division of Virology, Antiviral Drug & Vaccine Research, Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), Leuven, Belgium.
Elke MaasKU Leuven Department of Microbiology, Immunology & Transplantation, Rega Institute, Division of Virology, Antiviral Drug & Vaccine Research, Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), Leuven, Belgium.
Joran DegryseKU Leuven Department of Microbiology, Immunology & Transplantation, Rega Institute, Division of Virology, Antiviral Drug & Vaccine Research, Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), Leuven, Belgium.ORCID 0009-0005-6730-4302 Birgit WeynandKU Leuven Department of Imaging and Pathology, Translational Cell and Tissue Research, Division of Translational Cell and Tissue Research, Leuven, Belgium.
Hilde Van de VeldeBrussels Health Campus/Faculty of Medicine and Pharmacy, Research Group Genetics, Reproduction and Development, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Johan NeytsKU Leuven Department of Microbiology, Immunology & Transplantation, Rega Institute, Virology, Antiviral Drug and Vaccine Research Group, Leuven, Belgium.ORCID 0000-0002-0033-7514 Katrien De ClercqKU Leuven Department of Development and Regeneration, Implantation, Placentation and Pregnancy Research Group, Leuven, Belgium.
Yeranddy A AlpizarKU Leuven Department of Microbiology, Immunology & Transplantation, Rega Institute, Division of Virology, Antiviral Drug & Vaccine Research, Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), Leuven, Belgium. yeranddy.aguiaralpizar@kuleuven.be.ORCID 0000-0003-1959-5393 Kai DallmeierKU Leuven Department of Microbiology, Immunology & Transplantation, Rega Institute, Division of Virology, Antiviral Drug & Vaccine Research, Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), Leuven, Belgium. kai.dallmeier@kuleuven.be.ORCID 0000-0002-8117-9166 Funding
European Union Horizon Europe ProgramEuropean Union MSCA4Ukraine fellowshipFlemish Research FoundationFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 40007527Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0H3120NH.V.V. and K.D.; Excellence of ScienceKU Leuven (Katholieke Universiteit Leuven) C14/24/152KU Leuven (Katholieke Universiteit Leuven) GSF/25/074
6 · The paper itselfAbstract
Pregnant women are at higher risk of severe COVID-19, with vaccine access and hesitancy remaining a challenge. Here, we use a pregnant female hamster model of COVID-19 to explore the effects of maternal infection on pregnancy, revealing a significant increase in intrauterine growth restriction (IUGR) due to placental inflammation. Viral infection causes bronchopneumonia and weight loss in infected dams, but no vertical transmission occurs. IUGR is instead linked to placental damage, characterized by fibrin deposition, thrombosis, and elevated placental expression of IP10, IL6, and IL10, irrespective of fetal sex. Enoxaparin treatment reduces placental damage and improves fetal outcomes, while vaccination enhances viral clearance, protects the placenta, and reduces the risk of IUGR. These findings underscore placentitis as a key driver of fetal complications upon SARS-CoV-2 infection and highlight the potential of vaccination and anticoagulant therapy to protect both mother and child.
Indexed as
COVID-19Fetal DevelopmentFetal Growth RetardationPlacentaPregnancy Complications, InfectiousAnimalsAnticoagulantsCricetinaeDisease Models, AnimalEnoxaparinFemaleInflammationPregnancySARS-CoV-2AnticoagulantsEnoxaparin
Identifiers
PMID41663418
PMCPMC12996326
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390